Shire Supports Rare Disease Day 2013

                     Shire Supports Rare Disease Day 2013

PR Newswire

LEXINGTON, Massachusetts, February 28, 2013

LEXINGTON, Massachusetts, February 28, 2013 /PRNewswire/ --

- Global Initiatives Underscore Company's Long-Term Commitment to the Rare
Disease Community

Shire plc (LSE: SHP, NASDAQ: SHPG) today announced its support of Rare Disease
Day, joining patients, healthcare providers, and patient organizations around
the world to support a day that focuses attention on rare diseases as a public
health issue, and highlights the need for more understanding and awareness
about these diseases.

Observed annually on the last day of February, Rare Disease Day is coordinated
at the international level by the European Organisation for Rare Diseases
(EURORDIS) and the National Organization for Rare Disorders (NORD) in the US.
The Rare Disease Day 2013 slogan is "Rare Disorders Without Borders" to convey
the global solidarity of the rare disease community worldwide and the need for
collaboration and mutual support in the field of rare diseases.

According to EURORDIS and NORD there are between 6,000 and 8,000 known rare
diseases affecting approximately 30 million Europeans and 30 million
Americans. As a leader in rare diseases, Shire's Human Genetic Therapies (HGT)
business focuses its work on researching, developing, and marketing therapies
for Fabry disease, Hereditary Angioedema, Hunter syndrome, and Gaucher
disease, and has built and invested in a pipeline of innovative products and
solutions for rare diseases.

"Shire's purpose is to enable people with life-altering conditions to lead
better lives - and for us, this includes improving access to information and
diagnosis as well as providing much-needed treatment for rare diseases," said
Sylvie Grégoire, President of HGT. "Rare Disease Day is an occasion to show
our commitment to the rare disease community. We hope that this day can
highlight the need for consistent, reliable, and effective treatments and
services for patients and give hope to those affected by rare diseases."

Shire's Global Rare Disease Day Initiatives

As part of its external initiatives, Shire is supporting the R.A.R.E Project,
a leading non-profit rare disease advocacy organization, in their Global Genes
Project "Wear That You Care^™" denim campaign in which denim jeans are used to
raise awareness of rare genetic disorders. The company distributed over 3,500
blue ribbons to employees at various corporate locations worldwide.

Shire is also supporting a variety of other initiatives surrounding Rare
Disease Day, including: EURORDIS "Black Pearl" Gala Dinner on February 26^th
in Brussels; MassBio's Rare Disease Day celebration at the State House in
Boston on February 28^th; the "Troisième Journée des Maladies Rares en Suisse"
in Zürich, Switzerland on February 23^rd; the Royal Free Hospital in London in
the development of films to give insights into the patient journey for rare
conditions, Fabry disease and Gaucher disease; a special "Supplement on Rare
Diseases" in the UK's Independent newspaper; The National Action Day for Rare
Diseases organised by the University of Cologne on March 2^nd; the launch of
"Rare Voices Australia" (RVA) in Canberra in March 2013; and the "Awareness
Campaign on Rare Diseases", called for by the Federation on Rare Diseases of
Argentina (FADEPOF).


Shire enables people with life-altering conditions to lead better lives.

Through our deep understanding of patients' needs, we develop and provide
healthcare in the areas of:

  oBehavioral Health and Gastro Intestinal conditions
  oRare Diseases
  oRegenerative Medicine

as well as other symptomatic conditions treated by specialist physicians.

We aspire to imagine and lead the future of healthcare, creating value for
patients, physicians, policymakers, payors and our shareholders.


Statements included in this announcement that are not historical facts are
forward-looking statements. Forward-looking statements involve a number of
risks and uncertainties and are subject to change at any time. In the event
such risks or uncertainties materialize, Shire's results could be materially
adversely affected. The risks and uncertainties include, but are not limited
to, that:

  oShire's products may not be a commercial success;
  orevenues from ADDERALL XR are subject to generic erosion;
  othe failure to obtain and maintain reimbursement, or an adequate level of
    reimbursement, by third-party payors in a timely manner for Shire's
    products may impact future revenues and earnings;
  oShire relies on a single source for manufacture of certain of its products
    and a disruption to the supply chain for those products may result in
    Shire being unable to continue marketing or developing a product or may
    result in Shire being unable to do so on a commercially viable basis;
  oShire uses third party manufacturers to manufacture many of its products
    and is reliant upon third party contractors for certain goods and
    services, and any inability of these third party manufacturers to
    manufacture products, or any failure of these third party contractors to
    provide these goods and services, in each case in accordance with its
    respective contractual obligations, could adversely affect Shire's ability
    to manage its manufacturing processes or to operate its business;
  othe development, approval and manufacturing of Shire's products is subject
    to extensive oversight by various regulatory agencies and regulatory
    approvals or interventions associated with changes to manufacturing sites,
    ingredients or manufacturing processes could lead to significant delays,
    increase in operating costs, lost product sales, an interruption of
    research activities or the delay of new product launches;
  othe actions of certain customers could affect Shire's ability to sell or
    market products profitably and fluctuations in buying or distribution
    patterns by such customers could adversely impact Shire's revenues,
    financial conditions or results of operations;
  oinvestigations or enforcement action by regulatory authorities or law
    enforcement agencies relating to Shire's activities in the highly
    regulated markets in which it operates may result in the distraction of
    senior management, significant legal costs and the payment of substantial
    compensation or fines;
  oadverse outcomes in legal matters and other disputes, including Shire's
    ability to obtain, maintain, enforce and defend patents and other
    intellectual property rights required for its business, could have a
    material adverse effect on Shire's revenues, financial condition or
    results of operations;

and other risks and uncertainties detailed from time to time in Shire's
filings with the U.S. Securities and Exchange Commission, including its most
recent Annual Report on Form 10-K.

For further information please contact:

Jessica Mann

Jessica Cotrone

Nicole Barraud

SOURCE Shire plc
Press spacebar to pause and continue. Press esc to stop.